tiprankstipranks
Trending News
More News >
Fine Foods & Pharmaceuticals N.T.M. SpA (IT:FF)
:FF
Italy Market

Fine Foods & Pharmaceuticals N.T.M. SpA (FF) AI Stock Analysis

Compare
7 Followers

Top Page

IT

Fine Foods & Pharmaceuticals N.T.M. SpA

(FF)

Rating:64Neutral
Price Target:
€8.00
▼(-1.23%Downside)
The company's overall stock score is driven primarily by its moderate financial health and positive technical indicators, despite valuation concerns. The financial performance, characterized by a strong equity position and improving cash flow, is the most significant factor. Technical analysis indicates a positive trend, though the valuation suggests potential overvaluation.
Positive Factors
Financial Performance
1Q25 was the best ever in terms of EBITDA and margin, achieved fully organically and through traditional actions.
Growth Strategy
The company's positive qualitative outlook for FY25 is supported by a strong order backlog and existing multi-year agreements.
Negative Factors
Business Unit Performance
The Nutra business unit is expected to have slower growth assumptions, leading to a slight reduction in group revenue.
Revenue Growth
A relatively challenging YoY comparison and different order phasing led to a drop in group revenues.

Fine Foods & Pharmaceuticals N.T.M. SpA (FF) vs. iShares MSCI Italy ETF (EWI)

Fine Foods & Pharmaceuticals N.T.M. SpA Business Overview & Revenue Model

Company DescriptionFine Foods & Pharmaceuticals N.T.M. S.p.A. engages in the contract development and manufacturing of oral solid forms for the pharmaceutical and nutraceutical industries. It offers pharmaceutical products, including powders and granules, capsules, tablets, film-coated tablets, effervescent granules, and hard gelatine capsules. The company also provides nutraceutical products comprising soluble and effervescent powders and granules, soluble, effervescent and chewable tablets, fast melting/sublingual tablets, film-coated tablets, and hard gelatin capsules for various therapeutic areas, such as probiotics, multivitamins and minerals, immune systems, sleep and relax, gastrointestinal system, circulatory system, osteoarticular system, urinary system, women health, beauty, healthy ageing, and mental wellbeing. In addition, the company manufactures and trades in cosmetics products consisting of hair care, skin care, liquid detergents for personal hygiene, skin care emulsions, oral hygiene, deodorants, alcohol-based perfumery, bath and shower gel, shampoo and conditioners, shaping waxes, mouthwash and breath products, creams, gel and toothpaste, roll-on, stick and vapo spray deodrants, intimate cleansers, emulsions and microemulsions, gels, and liquid soaps; medical surgical aids and medical devices; antiseptics for undamaged skin, hand gel, pre-injection, hydroalcoholic surfaces, and iodine; and orthodontic cleaning tablets, disinfectants, and decongestant nasal sprays. The company was founded in 1984 and is headquartered in Verdellino, Italy.
How the Company Makes MoneyFine Foods & Pharmaceuticals N.T.M. SpA generates revenue primarily through its contract development and manufacturing services. The company's key revenue streams include the production and supply of pharmaceuticals, nutraceuticals, and cosmetics for third-party brands. FF partners with pharmaceutical and consumer health companies to develop and manufacture products under their brand names, providing end-to-end solutions that include formulation, production, and packaging. The company benefits from long-term contracts and significant repeat business from its clients, leveraging its expertise and state-of-the-art facilities to meet stringent quality standards and regulatory requirements. Strategic partnerships and a strong focus on innovation further bolster FF's earnings, enabling it to maintain a competitive edge in the CDMO market.

Fine Foods & Pharmaceuticals N.T.M. SpA Financial Statement Overview

Summary
Fine Foods & Pharmaceuticals N.T.M. SpA exhibits moderate financial health with stable profitability in a competitive industry. Revenue growth faces challenges, but the company has a solid equity position and effective cash flow management. Focus should be on enhancing operational efficiency and driving consistent revenue growth.
Income Statement
62
Positive
The company shows moderate profitability with a gross profit margin of approximately 41.8% and a net profit margin of 3.3% as of 2024. Revenue growth has been inconsistent, with a decline in 2024 compared to 2023. EBIT and EBITDA margins remain relatively low, indicating room for improvement in operational efficiency.
Balance Sheet
55
Neutral
The balance sheet shows a moderate debt-to-equity ratio of 0.41, indicating reliance on equity over debt. The equity ratio is strong at 54.4%, reflecting a solid equity base. However, the return on equity is low at 6.2%, suggesting limited profitability relative to shareholder investment.
Cash Flow
71
Positive
Cash flow performance is improving, with free cash flow turning positive in 2024. The operating cash flow to net income ratio is robust at 5.62, reflecting strong cash generation relative to earnings. The free cash flow to net income ratio is 1.36, indicating effective cash management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue243.75M251.81M206.85M194.42M173.03M
Gross Profit80.13M68.56M53.63M55.89M49.23M
EBITDA30.90M19.29M3.64M9.86M28.80M
Net Income8.16M-3.52M-9.50M-1.43M13.36M
Balance Sheet
Total Assets242.59M241.56M299.82M302.81M207.44M
Cash, Cash Equivalents and Short-Term Investments19.21M19.15M76.74M95.09M74.95M
Total Debt54.53M66.39M120.36M110.76M21.19M
Total Liabilities110.53M114.61M166.53M155.59M66.43M
Stockholders Equity132.06M126.95M133.29M147.22M141.01M
Cash Flow
Free Cash Flow11.12M-329.75K-12.30M-21.75M14.66M
Operating Cash Flow45.85M18.54M3.69M-5.83M30.47M
Investing Cash Flow-31.56M45.89M-15.31M-36.35M-12.34M
Financing Cash Flow-14.08M-55.66M4.74M55.95M-17.41M

Fine Foods & Pharmaceuticals N.T.M. SpA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8.10
Price Trends
50DMA
7.43
Positive
100DMA
7.07
Positive
200DMA
7.46
Positive
Market Momentum
MACD
0.17
Negative
RSI
68.41
Neutral
STOCH
75.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:FF, the sentiment is Positive. The current price of 8.1 is above the 20-day moving average (MA) of 7.63, above the 50-day MA of 7.43, and above the 200-day MA of 7.46, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 68.41 is Neutral, neither overbought nor oversold. The STOCH value of 75.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:FF.

Fine Foods & Pharmaceuticals N.T.M. SpA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
$26.91B15.06-4.01%3.23%1.02%2.12%
ITFF
64
Neutral
€193.58M20.68
1.53%-4.22%
€118.89M13.429.43%2.99%
ITENV
€56.60M13.72
5.03%
ITHQF
€7.00M45.74
ITIWB
€194.75M8.63
2.43%
ITNWL
€741.05M4.54
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IT:FF
Fine Foods & Pharmaceuticals N.T.M. SpA
8.04
-1.20
-12.99%
GB:0GEJ
Valsoia SpA
10.30
0.82
8.65%
IT:ENV
Enervit S.p.A.
3.24
0.14
4.52%
IT:HQF
High Quality Food SpA
0.61
-0.02
-3.17%
IT:IWB
Italian Wine Brands S.p.A.
20.20
-0.73
-3.49%
IT:NWL
Newlat Food S.p.A.
17.40
5.14
41.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 05, 2025